Blind spots in the new International Society of Hypertension guidelines: physiologically individualized therapy for resistant hypertension based on renin/aldosterone phenotyping, and amiloride for Liddle phenotype

J David Spence^{1

2}

Affiliations

¹ Neurology & Clinical Pharmacology, Western University.
² Stroke Prevention & Atherosclerosis Research Centre, Robarts Research Institute, London, Ontario, Canada.

Comment

J David Spence. J Hypertens. 2020 Nov.

. 2020 Nov;38(11):2338.

doi: 10.1097/HJH.0000000000002611.

J David Spence^{1

2}

¹ Neurology & Clinical Pharmacology, Western University.
² Stroke Prevention & Atherosclerosis Research Centre, Robarts Research Institute, London, Ontario, Canada.

No abstract available

Comment in

Reply.
Schlaich MP, Borghi C, Tomaszewski M, Stergiou GS, Schutte AE, Unger T; 2020 ISH Global Hypertension Practice Guidelines Committee. Schlaich MP, et al. J Hypertens. 2020 Nov;38(11):2339-2340. doi: 10.1097/HJH.0000000000002612. J Hypertens. 2020. PMID: 33027116 No abstract available.

2020 International Society of Hypertension global hypertension practice guidelines.
Unger T, Borghi C, Charchar F, Khan NA, Poulter NR, Prabhakaran D, Ramirez A, Schlaich M, Stergiou GS, Tomaszewski M, Wainford RD, Williams B, Schutte AE. Unger T, et al. J Hypertens. 2020 Jun;38(6):982-1004. doi: 10.1097/HJH.0000000000002453. J Hypertens. 2020. PMID: 32371787 No abstract available.

1. Unger T, Borghi C, Charchar F, Khan NA, Poulter NR, Prabhakaran D, et al. 2020 International Society of Hypertension global hypertension practice guidelines. J Hypertens 2020; 38:982–1004.
1. Williams B, MacDonald TM, Morant SV, Webb DJ, Sever P, McInnes GT, et al. Endocrine and haemodynamic changes in resistant hypertension, and blood pressure responses to spironolactone or amiloride: the PATHWAY-2 mechanisms substudies. Lancet Diabetes Endocrinol 2018; 6:464–475.
1. Laffer CL, Elijovich F, Eckert GJ, Tu W, Pratt JH, Brown NJ. Genetic variation in CYP4A11 and blood pressure response to mineralocorticoid receptor antagonism or ENaC inhibition: an exploratory pilot study in African Americans. J Am Soc Hypertens 2014; 8:475–480.
1. Baker EH, Duggal A, Dong Y, Ireson NJ, Wood M, Markandu ND, et al. Amiloride, a specific drug for hypertension in black people with T594M variant? Hypertension 2002; 40:13–17.
1. Spence JD, Rayner BL. Hypertension in Blacks: individualized therapy based on renin/aldosterone phenotyping. Hypertension 2018; 72:263–269.